The stock of Amedisys Incorporated (NASDAQ:AMED) registered a decrease of 9.19% in short interest. AMED’s total short interest was 1.13M shares in September as published by FINRA. Its down 9.19% from 1.24M shares, reported previously. With 241,100 shares average volume, it will take short sellers 5 days to cover their AMED’s short positions. The short interest to Amedisys Incorporated’s float is 3.44%. The stock decreased 1.09% or $0.53 during the last trading session, hitting $48.29. About 220,653 shares traded hands. Amedisys Inc (NASDAQ:AMED) has risen 51.71% since February 8, 2016 and is uptrending. It has outperformed by 35.22% the S&P500.
Amedisys, Inc. is a provider of home health and hospice services. The company has a market cap of $1.63 billion. The Firm offers home health services to the chronic, co-morbid, aging American population. It has a 42.26 P/E ratio. The Firm operates through three divisions: home health, hospice and personal care.
The institutional sentiment decreased to 0.88 in Q2 2016. Its down 0.21, from 1.09 in 2016Q1. The ratio worsened, as 23 funds sold all Amedisys Inc shares owned while 55 reduced positions. 17 funds bought stakes while 52 increased positions. They now own 29.42 million shares or 0.50% more from 29.27 million shares in 2016Q1.
First Light Asset Management Llc holds 2.82% of its portfolio in Amedisys Inc for 120,778 shares. Kohlberg Kravis Roberts & Co. L.P. owns 4.84 million shares or 2.57% of their US portfolio. Moreover, Timpani Capital Management Llc has 1.89% invested in the company for 88,261 shares. The Connecticut-based Sivik Global Healthcare Llc has invested 1.51% in the stock. Pier Capital Llc, a Connecticut-based fund reported 114,262 shares.
Out of 8 analysts covering Amedisys Inc. (NASDAQ:AMED), 2 rate it a “Buy”, 0 “Sell”, while 6 “Hold”. This means 25% are positive. Amedisys Inc. has been the topic of 11 analyst reports since November 6, 2015 according to StockzIntelligence Inc. RBC Capital Markets maintained the stock on May 6 with “Sector Perform” rating.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.